InspireMD

InspireMD P/CF

The P/CF (Price-to-Cash-Flow Ratio) of InspireMD (NSPR) as of Oct 16, 2026 is -2.06. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -3.31 — a change of -37.70% (higher).

P/CF

-2.06

YoY

-37.70%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of InspireMD is 2025 -2.06 . P/CF (Price-to-Cash-Flow Ratio) of InspireMD was 2024 -3.31 . It decreases by -37.70% higher compared to the previous year.

The InspireMD P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-9.53 USD
Jan 1, 2019
-7.39 USD
Jan 1, 2020
-7.98 USD
Jan 1, 2021
-5.48 USD
Jan 1, 2022
-4.66 USD
Jan 1, 2023
-4.42 USD
Jan 1, 2024
-3.31 USD
Jan 1, 2025
-2.06 USD
The InspireMD P/CF history
YEARP/CFYoY
-2.06-37.70%
-3.31-25.11%
-4.42-5.09%
-4.66-15.00%
-5.48-31.26%
-7.98+8.03%
-7.39-22.47%
-9.53+6.90%
-8.91-7.82%
-9.67+54.72%
-6.25+66.97%
-3.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InspireMD Stock analysis

What does InspireMD do? InspireMD Inc, listed on the stock market with ticker NSPR and ISIN US45779A8466, is a medical device company based in Tel Aviv-Yafo, Israel. The company operates within the Health Care sector, specifically in the Health Care industry. InspireMD has 127 employees and went public through an IPO on April 12, 2013. Its website is http://www.inspiremd.com/. The company focuses on developing and commercializing stent platform technology for treating complex vascular and coronary diseases. InspireMD's MicroNet is a micron mesh sleeve designed to wrap around a stent, providing embolic protection during stenting procedures. The company also offers the CGuard carotid embolic prevention system, which integrates MicroNet with a self-expandable nitinol stent for carotid artery applications. Additionally, InspireMD markets the MGuard Prime Embolic Protection System, a bare-metal cobalt-chromium stent, for coronary disease treatment in the European Union. The MGuard Prime EPS is also intended for use in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft coronary interventions. The company is developing a neurovascular flow diverter called NGuard, an endovascular device. InspireMD's technology aims to enhance safety and efficacy in vascular and coronary interventions by preventing embolic events during stent placement. InspireMD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InspireMD stock

P/CF (Price-to-Cash-Flow Ratio) of InspireMD is -2.06 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of InspireMD changed from -3.31 to -2.06, representing a -37.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) InspireMD since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s InspireMD with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — InspireMD

All Key Metrics — InspireMD